DCVax (R)-L-Developed by Northwest Biotherapeutics

作者：Polyzoidis Stavros^*; Ashkan Keyoumars

来源：Human Vaccines & Immunotherapeutics, 2014, 10(11): 3139-3145.

DOI：10.4161/hv.29276

• DCVax (R)-L
• glioblastoma multiforme
• immunotherapy
• vaccine
• dendritic cells
• overall survival
• side effects
• BBB
• blood brain barrier
• CNS
• central nervous system
• CTL
• cytotoxic T-lymphocyte
• DC
• dendritic cell
• DTH
• delayed tissue hypersensitivity
• EORTC
• European Organization for Research and Treatment of Cancer
• FDA
• Food and Drug Administration
• GBM
• glioblastoma multiforme
• GM-CSF
• granulocyte-macrophage colony-stimulating factor
• HGG
• high-grade glioma
• IL-4
• interleukin-4
• IMP

Dendritic cell (DC) immunotherapy is emerging as a potential addition to the standard of care in the treatment of glioblastoma multiforme (GBM). In the last decade or so various research groups have conducted phase I and II trials of DC-immunotherapy on patients with newly diagnosed (ND) and recurrent GBM and other high-grade gliomas in an attempt to improve the poor prognosis. Results show an increase in overall survival (OS), while vaccination-related side effects are invariably mild. Northwest Biotherapeutics, Inc., Bethesda, Maryland, U.S.A. (NWBT) developed the DCVax (R)-L vaccine as an adjunct to the treatment of GBM. It is currently under evaluation in a phase III trial in patients with ND-GBM, which is the only ongoing trial of its kind. In this review current data and perspectives of this product are examined.

• 出版日期2014-11